In an effort to investigate whether RARβ2 hypermethylation contributes to the development of recurrence in NSCLC according to statuses of smoking and interacting proteins, we analyzed the methylation status of RARβ2 and the expression statuses of cyclin D1, E-cadherin, β-catenin, EGFR, and c-MET in 578 NSCLC patients. The gene discussed is MET; the disease is non-small cell lung carcinoma.